Latest news for  (AMEX:CTEST) Stock

Wells Fargo analyst Gary Mobley initiates coverage on Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Overweight rating and announces Price Target of $23.

News

Price Target

Initiation

Analyst Ratings

ALGM

Wells Fargo Initiates Coverage On Allegro Microsystems with Overweight Rating, Announces Price Target of $23

Leerink Partners analyst Jeffrey La Rosa initiates coverage on Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) with a Outperform rating and announces Price Target of $79.

JANX

Leerink Partners Initiates Coverage On Janux Therapeutics with Outperform Rating, Announces Price Target of $79

Keybanc analyst Tim Rezvan maintains Gulfport Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPOR#NYSE">GPOR</a>) with a Overweight and raises the price target from $165 to $205.

GPOR

Keybanc Maintains Overweight on Gulfport Energy, Raises Price Target to $205

WIIM

APTO

Aptose Biosciences shares are trading lower after the company announced the pricing of an $8 million public offering.

Offerings

Aptose Biosciences Prices $8M Public Offering Of 40M Shares And 20M Warrants At $0.20 Per Unit; Warrants Priced At $0.25 Per Share And Expire In Five Years, With Closing Expected On November 25, 2024

Goldman Sachs analyst Adam Bubes initiates coverage on AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) with a Buy rating and announces Price Target of $130.

Goldman Sachs Initiates Coverage On AECOM with Buy Rating, Announces Price Target of $130

Wells Fargo analyst Joe Quatrochi initiates coverage on ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Overweight rating and announces Price Target of $155.

Wells Fargo Initiates Coverage On ARM Holdings with Overweight Rating, Announces Price Target of $155

SBFM

Sunshine Biopharma shares are trading higher after its Nora Pharma subsidiary launched Ursodiol, a generic version of URSO DS.

Keybanc analyst Steve Barger maintains AMETEK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) with a Overweight and raises the price target from $205 to $215.

Keybanc Maintains Overweight on AMETEK, Raises Price Target to $215

Confirmed By Nasdaq Listing Qualifications On November 21, 2024

NDRA

ENDRA Life Sciences Regains Compliance With Nasdaq Minimum Bid Price Rule

Sunshine Biopharma's Nora Pharma Subsidiary Launches Ursodiol, A Generic Version Of URSO DS

Goldman Sachs analyst Adam Bubes initiates coverage on EMCOR Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) with a Sell rating and announces Price Target of $445.

Goldman Sachs Initiates Coverage On EMCOR Group with Sell Rating, Announces Price Target of $445

UBS analyst David Vogt initiates coverage on Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Neutral rating and announces Price Target of $95.

UBS Initiates Coverage On Celestica with Neutral Rating, Announces Price Target of $95

Goldman Sachs analyst Ben Andrews initiates coverage on Flutter Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>) with a Buy rating and announces Price Target of $320.

FLUT

Goldman Sachs Initiates Coverage On Flutter Entertainment with Buy Rating, Announces Price Target of $320

Nano Labs Unveils Second-Generation V Series Crypto Mining Products With 5x Power Efficiency Boost And Enhanced Stability, Featuring Advanced Cuckoo 3.0 Chips In V2, V2H, And V2X Models

Applied Industrial Technologies To Acquire Hydradyne, Terms Not Disclosed; Applied Expects The Acquisition To Contribute Approximately $260M In Sales And $30M In EBITDA Before Anticipated Synergies

Biotech

General

HUMA

Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024

Johnson & Johnson Submits Supplemental Biologics License Application To FDA Seeking Approval Of Subcutaneous Induction Regimen Of TREMFYA

Evercore ISI Group analyst JESALYN Wong initiates coverage on Life Time Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTH#NYSE">LTH</a>) with a Outperform rating and announces Price Target of $29.

Evercore ISI Group Initiates Coverage On Life Time Group Hldgs with Outperform Rating, Announces Price Target of $29

UBS analyst Stephen Ju initiates coverage on Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) with a Buy rating and announces Price Target of $11.

Comments

News

Latest news for (AMEX:CTEST) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga